Vaxart, Inc. SEC filings VXRT
Vaxart, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 18, 2011. Its latest annual report, Form ARS, was filed on Jun 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DFAN14A | Filing | Jul 2, 2026 | — |
| DFAN14A | Filing | Jun 22, 2026 | — |
| DFAN14A | Filing | Jun 9, 2026 | — |
| DFAN14A | Filing | Jun 8, 2026 | — |
| DEFC14A | Filing | Jun 4, 2026 | — |
| DEFC14A | Proxy statement | Jun 1, 2026 | — |
| PRER14A | Proxy statement | May 29, 2026 | — |
| PRRN14A | Filing | May 29, 2026 | — |
| PREC14A | Filing | May 21, 2026 | — |
| PREC14A | Proxy statement | May 19, 2026 | — |
| EFFECT | Filing | May 18, 2026 | — |
| EFFECT | Filing | Apr 30, 2026 | — |
| CORRESP | Letter to the SEC | Apr 29, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2026 | — |
| 25-NSE | Delisting notice | Nov 21, 2025 | — |
| PX14A6G | Filing | Sep 18, 2025 | — |
| PX14A6G | Filing | Sep 10, 2025 | — |
| PX14A6G | Filing | Sep 2, 2025 | — |
| EFFECT | Filing | May 5, 2023 | — |
| CORRESP | Letter to the SEC | May 3, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2021 | — |
| CORRESP | Letter to the SEC | Jan 27, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 18, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2020 | — |
| EFFECT | Filing | Oct 2, 2019 | — |
| EFFECT | Filing | Sep 26, 2019 | — |
| CORRESP | Letter to the SEC | Sep 26, 2019 | — |
| CORRESP | Letter to the SEC | Sep 26, 2019 | — |
| CORRESP | Letter to the SEC | Sep 23, 2019 | — |
| CORRESP | Letter to the SEC | Sep 23, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2019 | — |
| EFFECT | Filing | Apr 11, 2019 | — |
| EFFECT | Filing | Apr 8, 2019 | — |
| CORRESP | Letter to the SEC | Apr 8, 2019 | — |
| CORRESP | Letter to the SEC | Apr 8, 2019 | — |
| EFFECT | Filing | Mar 15, 2019 | — |
| CORRESP | Letter to the SEC | Mar 14, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2019 | — |
| CORRESP | Letter to the SEC | Dec 27, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2018 | — |
| 425 | Form 8-k | Feb 9, 2018 | — |
| 425 | Form 425 | Feb 9, 2018 | — |
| DFAN14A | Filing | Feb 9, 2018 | — |
| CORRESP | Letter to the SEC | Feb 9, 2018 | — |
| 425 | Form 8-k | Feb 7, 2018 | — |
| 425 | Form 8-k | Feb 6, 2018 | — |
| 425 | Form 425 | Feb 1, 2018 | — |
| 425 | Form 425 | Feb 1, 2018 | — |
| 425 | Form 8-k | Feb 1, 2018 | — |
| DFAN14A | Filing | Jan 31, 2018 | — |
| DFAN14A | Filing | Jan 29, 2018 | — |
| 425 | Form 8-k | Jan 26, 2018 | — |
| 425 | Form 8-k | Jan 24, 2018 | — |
| 425 | Form 425 | Jan 24, 2018 | — |
| DFAN14A | Filing | Jan 24, 2018 | — |
| DFAN14A | Filing | Jan 23, 2018 | — |
| DEFC14A | Filing | Jan 23, 2018 | — |
| PRRN14A | Filing | Jan 19, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2018 | — |
| 425 | Form 8-k | Jan 17, 2018 | — |
| 425 | Form 425 | Jan 16, 2018 | — |
| PREC14A | Filing | Jan 12, 2018 | — |
| 425 | Form 8-k | Jan 12, 2018 | — |
| EFFECT | Filing | Dec 29, 2017 | — |
| CORRESP | Letter to the SEC | Dec 28, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2017 | — |
| 425 | Form 8-k | Dec 19, 2017 | — |
| 425 | Form 8-k | Oct 31, 2017 | — |
| 425 | Form 8-k | Oct 30, 2017 | — |
| CT ORDER | Filing | Jul 11, 2016 | — |
| EFFECT | Filing | Jul 15, 2015 | — |
| CORRESP | Letter to the SEC | Jul 13, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2015 | — |
| CT ORDER | Filing | May 21, 2015 | — |
| NT 10-K | Form nt 10-k | Sep 15, 2014 | Jun 30, 2014 |
| EFFECT | Filing | Oct 17, 2013 | — |
| CORRESP | Letter to the SEC | Oct 16, 2013 | — |
| NT 10-K | Form nt 10-k | Sep 13, 2013 | Jun 30, 2013 |
| UPLOAD | Letter from the SEC | Aug 22, 2013 | — |
| CT ORDER | Filing | Jun 14, 2013 | — |
| DFAN14A | Filing | Sep 20, 2012 | — |
| DFAN14A | Filing | Sep 14, 2012 | — |
| CORRESP | Letter to the SEC | Sep 7, 2012 | — |
| DFAN14A | Filing | Aug 29, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2012 | — |
| DFAN14A | Filing | Aug 16, 2012 | — |
| DEFC14A | Filing | Aug 10, 2012 | — |
| SC TO-I/A | Amendment no.3 to scto | Aug 2, 2012 | — |
| SC TO-I/A | Amendment no.2 to scto | Jul 31, 2012 | — |
| PRRN14A | Filing | Jul 20, 2012 | — |
| SC TO-I/A | Amendment no.1 to scto | Jul 19, 2012 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2012 | — |
| CORRESP | Letter to the SEC | Jul 16, 2012 | — |
| PREC14A | Preliminary proxy statement | Jul 13, 2012 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2012 | — |
| SC TO-I | Scto | Jul 2, 2012 | — |
| 11-K | Employee savings plan report | Jun 28, 2012 | Dec 31, 2011 |
| NO ACT | Auto-generated paper document | Jun 20, 2012 | Jun 18, 2012 |
| NO ACT | Auto-generated paper document | Jun 20, 2012 | Jun 18, 2012 |
| 8-A12B | Form 8a | Aug 25, 2011 | — |
| CT ORDER | Filing | Jul 12, 2011 | — |
| 11-K | Employee savings plan report | Jun 29, 2011 | Dec 31, 2010 |
Showing 108 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.